Baidu
map

J Hypertens:原发性高血压患者抗高血压药物依从性的影响因素分析!

2017-05-27 xing.T MedSci原创

由此可见,几个患者因素被确认作为抗高血压类药物类别和治疗依从性的决定因素;因此,它们可以帮助确定有不依从性风险的患者,因此可以针对它们进行依从性改善干预。

近日,高血压领域权威杂志Journal of Hypertension上发表了一篇研究文章,研究人员旨在探讨高血压患者服用抗高血压药物的整体(治疗依从性)与特定药物类别(药物类别依从性)依从性的相关因素。

该回顾性队列研究纳入了2006年4月至2013年3月期间来自于英国临床实践研究数据链中的原发性高血压患者。参与者从第一类降压药物(药物类别依从性)进入处方之日起,以及从第一次接触抗高血压药物(治疗依从性)之日起开始随访至研究结束、或病人离开数据库或死亡。研究人员记录参与者六类抗高血压药物的使用时间(从各类药物首次进入处方到随访结束的时间)。服用抗高血药物天数复盖比例(PDC)被用来估计随访期间高血压患者抗高血压药物治疗的治疗依从性以及每一类药特定的药物类别依从性。研究人员采用广义线性模型来评估PDC的相关因素。

在176835例患者和371605个处方中,中位数治疗和药物类别PDC分别为93.9和98.3%,分别有20%的患者和38.4%的处方PDC不到80%。较高的治疗和药物类别PDC与年龄增加、使用肾素血管紧张素药物,以及既往的病人和抗高血压药物使用者相关。较高的剥夺、多发性合并症和降压药物的切换与较低的PDC相关。

由此可见,几个患者因素被确认作为抗高血压类药物类别和治疗依从性的决定因素;因此,它们可以帮助确定有不依从性风险的患者,因此可以针对它们进行依从性改善干预。

原始出处:

Kurdi, Amanj I,et al. Exploring factors associated with patients' adherence to antihypertensive drugs among people with primary hypertension in the United Kingdom.Journal of Hypertension. 2017. http://journals.lww.com/jhypertension/Abstract/publishahead/Exploring_factors_associated_with_patients_.97733.aspx

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2043203, encodeId=e99a2043203b4, content=<a href='/topic/show?id=c1e83e138a7' target=_blank style='color:#2F92EE;'>#原发性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37138, encryptionId=c1e83e138a7, topicName=原发性高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Sep 17 06:49:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039773, encodeId=7c8a2039e7390, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun May 28 05:49:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032290, encodeId=e6012032290ce, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 23 00:49:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027105, encodeId=7d80202e10548, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Aug 20 19:49:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846545, encodeId=a3f91846545ad, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Apr 02 19:49:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038665, encodeId=53592038665d5, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Feb 19 05:49:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207064, encodeId=90bb20e064a9, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Jun 06 06:06:31 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726434, encodeId=942b1e264344e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 27 13:49:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465539, encodeId=fb1c1465539a2, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545675, encodeId=bd1d15456e505, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2043203, encodeId=e99a2043203b4, content=<a href='/topic/show?id=c1e83e138a7' target=_blank style='color:#2F92EE;'>#原发性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37138, encryptionId=c1e83e138a7, topicName=原发性高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Sep 17 06:49:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039773, encodeId=7c8a2039e7390, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun May 28 05:49:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032290, encodeId=e6012032290ce, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 23 00:49:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027105, encodeId=7d80202e10548, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Aug 20 19:49:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846545, encodeId=a3f91846545ad, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Apr 02 19:49:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038665, encodeId=53592038665d5, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Feb 19 05:49:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207064, encodeId=90bb20e064a9, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Jun 06 06:06:31 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726434, encodeId=942b1e264344e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 27 13:49:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465539, encodeId=fb1c1465539a2, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545675, encodeId=bd1d15456e505, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2043203, encodeId=e99a2043203b4, content=<a href='/topic/show?id=c1e83e138a7' target=_blank style='color:#2F92EE;'>#原发性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37138, encryptionId=c1e83e138a7, topicName=原发性高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Sep 17 06:49:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039773, encodeId=7c8a2039e7390, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun May 28 05:49:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032290, encodeId=e6012032290ce, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 23 00:49:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027105, encodeId=7d80202e10548, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Aug 20 19:49:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846545, encodeId=a3f91846545ad, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Apr 02 19:49:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038665, encodeId=53592038665d5, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Feb 19 05:49:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207064, encodeId=90bb20e064a9, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Jun 06 06:06:31 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726434, encodeId=942b1e264344e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 27 13:49:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465539, encodeId=fb1c1465539a2, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545675, encodeId=bd1d15456e505, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2043203, encodeId=e99a2043203b4, content=<a href='/topic/show?id=c1e83e138a7' target=_blank style='color:#2F92EE;'>#原发性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37138, encryptionId=c1e83e138a7, topicName=原发性高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Sep 17 06:49:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039773, encodeId=7c8a2039e7390, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun May 28 05:49:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032290, encodeId=e6012032290ce, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 23 00:49:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027105, encodeId=7d80202e10548, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Aug 20 19:49:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846545, encodeId=a3f91846545ad, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Apr 02 19:49:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038665, encodeId=53592038665d5, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Feb 19 05:49:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207064, encodeId=90bb20e064a9, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Jun 06 06:06:31 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726434, encodeId=942b1e264344e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 27 13:49:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465539, encodeId=fb1c1465539a2, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545675, encodeId=bd1d15456e505, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2043203, encodeId=e99a2043203b4, content=<a href='/topic/show?id=c1e83e138a7' target=_blank style='color:#2F92EE;'>#原发性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37138, encryptionId=c1e83e138a7, topicName=原发性高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Sep 17 06:49:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039773, encodeId=7c8a2039e7390, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun May 28 05:49:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032290, encodeId=e6012032290ce, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 23 00:49:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027105, encodeId=7d80202e10548, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Aug 20 19:49:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846545, encodeId=a3f91846545ad, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Apr 02 19:49:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038665, encodeId=53592038665d5, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Feb 19 05:49:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207064, encodeId=90bb20e064a9, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Jun 06 06:06:31 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726434, encodeId=942b1e264344e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 27 13:49:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465539, encodeId=fb1c1465539a2, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545675, encodeId=bd1d15456e505, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2043203, encodeId=e99a2043203b4, content=<a href='/topic/show?id=c1e83e138a7' target=_blank style='color:#2F92EE;'>#原发性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37138, encryptionId=c1e83e138a7, topicName=原发性高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Sep 17 06:49:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039773, encodeId=7c8a2039e7390, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun May 28 05:49:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032290, encodeId=e6012032290ce, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 23 00:49:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027105, encodeId=7d80202e10548, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Aug 20 19:49:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846545, encodeId=a3f91846545ad, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Apr 02 19:49:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038665, encodeId=53592038665d5, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Feb 19 05:49:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207064, encodeId=90bb20e064a9, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Jun 06 06:06:31 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726434, encodeId=942b1e264344e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 27 13:49:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465539, encodeId=fb1c1465539a2, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545675, encodeId=bd1d15456e505, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2043203, encodeId=e99a2043203b4, content=<a href='/topic/show?id=c1e83e138a7' target=_blank style='color:#2F92EE;'>#原发性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37138, encryptionId=c1e83e138a7, topicName=原发性高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Sep 17 06:49:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039773, encodeId=7c8a2039e7390, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun May 28 05:49:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032290, encodeId=e6012032290ce, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 23 00:49:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027105, encodeId=7d80202e10548, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Aug 20 19:49:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846545, encodeId=a3f91846545ad, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Apr 02 19:49:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038665, encodeId=53592038665d5, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Feb 19 05:49:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207064, encodeId=90bb20e064a9, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Jun 06 06:06:31 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726434, encodeId=942b1e264344e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 27 13:49:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465539, encodeId=fb1c1465539a2, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545675, encodeId=bd1d15456e505, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
    2017-06-06 laoli

    学习了,谢谢分享!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2043203, encodeId=e99a2043203b4, content=<a href='/topic/show?id=c1e83e138a7' target=_blank style='color:#2F92EE;'>#原发性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37138, encryptionId=c1e83e138a7, topicName=原发性高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Sep 17 06:49:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039773, encodeId=7c8a2039e7390, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun May 28 05:49:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032290, encodeId=e6012032290ce, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 23 00:49:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027105, encodeId=7d80202e10548, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Aug 20 19:49:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846545, encodeId=a3f91846545ad, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Apr 02 19:49:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038665, encodeId=53592038665d5, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Feb 19 05:49:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207064, encodeId=90bb20e064a9, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Jun 06 06:06:31 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726434, encodeId=942b1e264344e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 27 13:49:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465539, encodeId=fb1c1465539a2, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545675, encodeId=bd1d15456e505, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
    2018-03-27 feather89
  9. [GetPortalCommentsPageByObjectIdResponse(id=2043203, encodeId=e99a2043203b4, content=<a href='/topic/show?id=c1e83e138a7' target=_blank style='color:#2F92EE;'>#原发性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37138, encryptionId=c1e83e138a7, topicName=原发性高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Sep 17 06:49:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039773, encodeId=7c8a2039e7390, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun May 28 05:49:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032290, encodeId=e6012032290ce, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 23 00:49:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027105, encodeId=7d80202e10548, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Aug 20 19:49:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846545, encodeId=a3f91846545ad, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Apr 02 19:49:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038665, encodeId=53592038665d5, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Feb 19 05:49:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207064, encodeId=90bb20e064a9, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Jun 06 06:06:31 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726434, encodeId=942b1e264344e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 27 13:49:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465539, encodeId=fb1c1465539a2, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545675, encodeId=bd1d15456e505, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=2043203, encodeId=e99a2043203b4, content=<a href='/topic/show?id=c1e83e138a7' target=_blank style='color:#2F92EE;'>#原发性高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37138, encryptionId=c1e83e138a7, topicName=原发性高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Sun Sep 17 06:49:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039773, encodeId=7c8a2039e7390, content=<a href='/topic/show?id=bf0f5584ef6' target=_blank style='color:#2F92EE;'>#抗高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55847, encryptionId=bf0f5584ef6, topicName=抗高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun May 28 05:49:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032290, encodeId=e6012032290ce, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Feb 23 00:49:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027105, encodeId=7d80202e10548, content=<a href='/topic/show?id=5dd1558503e' target=_blank style='color:#2F92EE;'>#抗高血压药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55850, encryptionId=5dd1558503e, topicName=抗高血压药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=362b271, createdName=zexyw01, createdTime=Sun Aug 20 19:49:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846545, encodeId=a3f91846545ad, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Apr 02 19:49:00 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038665, encodeId=53592038665d5, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Feb 19 05:49:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207064, encodeId=90bb20e064a9, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Jun 06 06:06:31 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726434, encodeId=942b1e264344e, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Mar 27 13:49:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465539, encodeId=fb1c1465539a2, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545675, encodeId=bd1d15456e505, content=<a href='/topic/show?id=a383558515b' target=_blank style='color:#2F92EE;'>#抗高血压药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55851, encryptionId=a383558515b, topicName=抗高血压药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46713811513, createdName=ms9474365431325850, createdTime=Mon May 29 13:49:00 CST 2017, time=2017-05-29, status=1, ipAttribution=)]

相关资讯

J Hypertens:老年高血压患者的体力活动与认知功能有啥关系?

由此可见,在全国高血压老年人样本中,符合体力活动指南的参与者与较高的认知功能有关。

J Hypertens:替米沙坦比氢氯噻嗪降舒张压更优

对于饮食喜咸,多药联合依从性又不好的轻中度高血压患者,采用单药治疗效果如何?近期,北京大学医学部乔治健康研究所和北京大学人民医院学者发表于J Hypertens上的一项研究表明,对于这部分患者,每天40 mg的替米沙坦或25 mg的氢氯噻嗪都有效,而前者降压效果明显更好,尤其是舒张压。研究显示,在接受替米沙坦或氢氯噻嗪的两组轻中度高血压患者,治疗后15天、30天和60天时,替米沙坦组平均收缩压/舒

J Hypertens:高血压患者常规尿液检测抗高血压药物治疗依从性分析!

这些结果表明门诊就诊患者有良好的抗高血压药物治疗依从性。研究人员认为通过超高效液相色谱-串联质谱法的抗高血压药物尿液检测是一个准确、实用的直接监测服药依从性的工具。这种直接的信息与自我报告的问卷并不重叠。

JAMA Intern Med:强化降压对老年人步态速度和移动限制有何影响?

目标收缩压低于120 mm Hg对年龄≥75岁高血压老人的步态速度有影响吗?2017年4月,发表在《JAMA Intern Med》的一项有2636例个体的随机临床试验表明,在3年的随访期内,强化降压(目标收缩压小于120 mm Hg)和标准治疗(目标收缩压小于140 mm Hg)在步态速度和移动限制方面没有差异。重要性:强化血压(BP)控制对心血管发病率和死亡率显示获益;其是否会对身体功能结局产

BMJ:55岁前发生的高血压遗传,心血管死亡风险更高

波士顿大学医学院研究人员分析了弗明汉心脏研究中两代受试者的高血压发病及心血管死亡情况表明:早发(<55岁)高血压与其子女发生高血压密切相关,而且与晚发高血压相比,早发高血压的心血管死亡风险更高。研究者发现,如果父母中有一位或者两位是早发高血压,子女患高血压风险分别增加1倍和2.5倍。而晚发高血压患者的子女患高血压风险与无高血压者子女相当。本研究数据显示,在父辈这一代3614例受试者中,随访6

J Hypertens:叶酸治疗降低大量蛋白尿的高血压患者死亡风险!

由此可见,在没有主要心血管疾病史的高血压患者中,叶酸治疗可以降低重度蛋白尿患者相关的死亡风险。

Baidu
map
Baidu
map
Baidu
map